A phase II study of weekly docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer.

Introduction: The combination of docetaxel and cisplatin is an effective first-line regimen in patients with advanced non-small cell lung cancer. However, the recommended three-weekly schedule is associated with frequent neutropenia and infections. Because of the toxicity of cisplatin, patients may need to be hospitalized to ensure adequate hydration.